Novanta Inc. (NOVT)
| Market Cap | 5.54B +21.7% |
| Revenue (ttm) | 1.00B +5.6% |
| Net Income | 53.72M -23.9% |
| EPS | 1.41 -27.6% |
| Shares Out | 35.61M |
| PE Ratio | 110.18 |
| Forward PE | 41.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 536,905 |
| Open | 156.06 |
| Previous Close | 155.30 |
| Day's Range | 154.52 - 157.98 |
| 52-Week Range | 98.27 - 171.85 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 175.00 (+12.43%) |
| Earnings Date | Aug 4, 2026 |
About NOVT
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment s... [Read more]
Financial Performance
In 2025, Novanta's revenue was $980.60 million, an increase of 3.30% compared to the previous year's $949.25 million. Earnings were $53.83 million, a decrease of -16.01%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NOVT stock is "Strong Buy." The 12-month stock price target is $175.0, which is an increase of 12.43% from the latest price.
News
Novanta Transcript: M&A announcement
The acquisition of Riverpoint Medical accelerates expansion into high-growth surgical consumables, is immediately accretive, and brings significant synergies and recurring revenue growth. The deal strengthens market position, leverages existing customer relationships, and sets a platform for future expansion.
Novanta Slides: M&A announcement
Novanta has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Novanta Press release: M&A announcement
Novanta issued a press release on June 9, 2026, disclosing material business information to investors.
Novanta price target raised to $180 from $173 at Baird
Baird analyst Quinn Fredrickson raised the firm’s price target on Novanta (NOVT) to $180 from $173 and keeps an Outperform rating on the shares.
Novanta announces $300M private placement
Novanta (NOVT) announced that it has entered into a securities purchase agreement for a private placement of the company’s common shares to institutional and other accredited investors that is expecte...
Novanta Inc. Announces $300 Million Private Placement
BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares (“Com...
Novanta acquires Riverpoint Medical for $1.45B
Novanta (NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a company providing minimally invasive surgical consumables, from Arlington Capital, a Washington D.C.-area privat...
Novanta Inc. Announces Acquisition of Riverpoint Medical
BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (“Novanta” or the “Company”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today ...
Novanta Transcript: 46th Annual William Blair Growth Stock Conference
Portfolio now over 50% medical, with reduced semiconductor exposure and strong focus on robotics, automation, and recurring revenue. Growth driven by innovation in medical consumables, intelligent subsystems, and GenAI-linked technologies, with double-digit growth targeted through organic and M&A strategies.
Novanta Transcript: AGM 2026
The meeting covered board introductions, review of 2025 financials, and voting on director elections, executive compensation, and auditor appointment. All proposals passed, and no shareholder questions were raised.
Novanta Slides: Investor presentation
Novanta has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Novanta to Present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta to Present at Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chie...
Novanta price target raised to $173 from $144 at Baird
Baird raised the firm’s price target on Novanta (NOVT) to $173 from $144 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results showing…
Novanta Earnings Call Transcript: Q1 2026
Q1 2026 saw double-digit bookings and revenue growth across all businesses, with strong cash flow and margin expansion despite tariff and cost headwinds. Guidance for 2026 was raised, supported by robust demand in AI, medical, and automation markets, and a strong acquisition pipeline.
Novanta Earnings release: Q1 2026
Novanta released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Novanta Quarterly report: Q1 2026
Novanta has published its Q1 2026 quarterly earnings report on May 12, 2026.
Novanta reports Q1 adjusted EPS 81c, consensus 78c
Reports Q1 revenue $257.7M, consensus $253.4M. “Novanta (NOVT) delivered another quarter of excellent bookings, growing 37% year-over-year and representing a 1.10 book-to-bill ratio, driven by continu...
Novanta sees Q2 adjusted EPS 81c-86c, consensus 86c
Sees Q2 revenue $259M-$264M, consensus $257.08M.
Novanta backs FY26 adjusted EPS view $3.50-$3.65, consensus $3.56
Raises FY26 revenue view to $1.04B-$1.055B from $1.03B-$1.05B, consensus $1.04B.
Novanta Announces Financial Results for the First Quarter 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta Proxy statement: Proxy filing
Novanta filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Novanta Inc. Announces Schedule of First Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 resul...
Novanta upgraded to Outperform from Neutral at Baird
Baird analyst Quinn Fredrickson upgraded Novanta (NOVT) to Outperform from Neutral with a price target of $144, down from $150. The firm remains positive on the advanced industrial technology group,…
Novanta Joins NVIDIA Halos AI Systems Inspection Lab
BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) announced today that it has joined NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited inspection...